Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs

doi:10.3748/wjg.v31.i4.101933

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 4

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4860)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

145

HTML

2212

Figures (1-2)

393

Tables (1-1)

387

Sum=3137

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

214

Download

545

Sum=759

Publishing Process of This Article

Item

Count

Browse

168

Download

612

Sum=780

Jan 28, 2025 (publication date) through Feb 19, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jan 28, 2025; 31(4): 101933
Published online Jan 28, 2025. doi: 10.3748/wjg.v31.i4.101933

Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs

Sergey M Kotelevets

Sergey M Kotelevets, Department of Therapy, North Caucasus State Academy, Cherkessk 369000, Russia

Author contributions: Kotelevets SM designed the overall concept and outline of the manuscript, wrote and edited the manuscript, and reviewed literatures.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Sergey M Kotelevets, MD, Department of Therapy, North Caucasus State Academy, 75/32 Lenina Street, Cherkessk 369000, Russia. smkotelevets@mail.ru

Received: October 1, 2024
Revised: November 8, 2024
Accepted: December 6, 2024
Published online: January 28, 2025
Processing time: 89 Days and 18.3 Hours

Core Tip

Core Tip: Helicobacter pylori (H. pylori) infection has a protective effect on gastroesophageal reflux disease. Both of these diseases have a very high incidence and prevalence. The main obstacle to effective treatment H. pylori infection and gastroesophageal reflux disease is the possible side effects after use of proton pump inhibitors (PPIs). The article provides a precise analysis of scientific reviews and meta-analyses, as well as experimental scientific morphological studies on this topic. The author presented his original field of vision. He convincingly substantiated his opinion, proposed to interpret possible morphological and functional changes in the gastric mucosa after long-term use of PPIs as compensatory mechanisms of sanogenesis. This field of view will increase the number of indications for the use of PPIs and other antisecretory drugs.